Valeant Pharmaceuticals (VRX) Looking Past Allergan - BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Valeant Pharma (VRX) Will Review Allergan/Actavis Deal; Can't Justify Paying $219/Share
November 17, 2014 9:31 AM ESTValeant Pharma (NYSE: VRX) commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan... More
Valeant Pharma (VRX) Falls as Allergan Goes with Actavis Deal
November 17, 2014 9:22 AM ESTValeant Pharma (NYSE: VRX) is trading down 1.3% early Monday after hostile-takeover target Allergan (NYSE: AGN) agreed to a $66 billion merger deal with Actavis (NYSE: ACT) instead.
... More